The advertisement addresses individuals diagnosed with early-stage non-small cell lung cancer (NSCLC) and presents surgery as a potential treatment option.
Creative Information
| CID: | 8fcc22e2-7708-489f-b8d6-c176f0be63e2 |
| CRID: | 2_206_449841 |
| Domain: | keytruda.com |
| Seat: | BSW |
| Size: | 300x250 |
| Bid: | $0.76 |
| Timestamp: | 11/4/2025, 4:11:33 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/20/2025, 4:53:33 PM | 6.84s | |
| adomain_analysis | success | 11/20/2025, 4:53:18 PM | 4.37s | |
| adomain_capture | success | 11/20/2025, 4:53:13 PM | 0.20s | |
| ad_render | success | 11/20/2025, 4:53:26 PM | 16.88s | |
| brand_mapping | success | 11/20/2025, 4:32:45 PM | 0.10s | |
Analysis Results
Ad Format: banner
Brands: Keytruda
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1365.29 KB | ||||||||||||||||||||||
| Render Time: | 7.94 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Total Ad Size: | 1384.46 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain
Ad Preview
Raw Ad Markup
<ins class='dcmads' style='display:inline-block;width:300px;height:250px' data-dcm-placement='N464015.3848558MATTERKIND/B32794367.409136625' data-dcm-rendering-mode='script' data-dcm-https-only data-dcm-keywords='359e0a65-c028-11f0-b6eb-42010ab20227' data-dcm-click-tracker='https%3A%2F%2Frtb.adentifi.com%2FClicks%3FcrId%3D449841%3BsId%3D719329%3BlId%3D91427%3BcId%3D17823%3BadExchange%3DBidSwitch%3Baction%3Dclick%3BadId%3D359e0a65-c028-11f0-b6eb-42010ab20227%3BadThdId%3D1ed5d5c8d8bc13c389c65c63e02f73eb%3BengineId%3D4901444860556412269%3BdIp%3DNzEuNjIuMTU3Ljkz%3BdIpv6%3D%3BadThdIdCode%3DWEB_MD5_V4%3BdealId%3D0%3BgeoId%3D126352%3BinventoryId%3D268127%3BrtdmIndicator%3D1%3Btimestamp%3D1762993937%3Blat%3DMzcuMjM%3Blong%3DLTgwLjQx%3Bdma%3DNTcz%3BstateCode%3D%3Bzip%3DMjQwNjA%3Bbsc%3D${CLICK_URL_ENC}%3Bredir%3D' data-dcm-resettable-device-id='' data-dcm-api-frameworks='[APIFRAMEWORKS]' data-dcm-omid-partner='[OMIDPARTNER]' data-dcm-gdpr-applies='gdpr=${GDPR}' data-dcm-gdpr-consent='gdpr_consent=${GDPR_CONSENT_755}' data-dcm-addtl-consent='addtl_consent=${ADDTL_CONSENT}' data-dcm-ltd='false' data-dcm-app-id=''> <script src='https://www.googletagservices.com/dcm/dcmads.js'></script></ins><img src='https://rtb.adentifi.com/Imps?impId=1;adId=359e0a65-c028-11f0-b6eb-42010ab20227;lId=91427;sId=719329;cId=17823;crId=449841;adThdId=1ed5d5c8d8bc13c389c65c63e02f73eb;adExchange=BidSwitch;engineId=4901444860556412269;dealId=0;geoId=126352;inventoryId=268127;rtdmIndicator=1;timestamp=1762993937;property=newsweek.com;dIp=NzEuNjIuMTU3Ljkz;dIpv6=;adThdIdCode=WEB_MD5_V4;thirdPartyIdType=1;npiKey=0;hhId=257931226;cuid=cuid_2e083e00-4342-11f0-a763-121a3bdf91f3' style='display:none; width:0px; height:0px;' /><script src="https://tags.bkrtx.com/js/bk-coretag.js"></script><script>bk_addPageCtx("id","cuid_2e083e00-4342-11f0-a763-121a3bdf91f3");bk_allow_multiple_calls = true;bk_use_multiple_iframes = true;bk_send_statid_payload = true;bk_use_image = true;bk_callback = true;bk_doJSTag(18840, 4);</script><img src='https://sb.scorecardresearch.com/p?c1=9&c2=16077523&c3=2&cs_xi=cuid_2e083e00-4342-11f0-a763-121a3bdf91f3&rn=359e0a65-c028-11f0-b6eb-42010ab20227' height='0' width='0' /><span id="te-clearads-js-adtheorent01cont449841"><script type="text/javascript" src="//choices.truste.com/ca?pid=adtheorent01&aid=adtheorent01&cid=17823&c=adtheorent01cont449841&w=300&h=250&js=pmw0&plc=tr&uid=1ed5d5c8d8bc13c389c65c63e02f73eb"></script></span><img src="https://us-east-sync.bidswitch.net/sync?ssp=kargo&dsp_id=206&imp=1" alt=" " style="display:none"/>Creatives
